Menopause Treatment

Perimenopause Mood Swings Are Not Menopause Mood Swings

Most women expect mood swings to peak after their periods stop. The opposite is true. Perimenopause is when mood destabilization hits hardest because the mechanism is fluctuation, not depletion. A postmenopausal woman with stable low estrogen has a depressed mood system. A perimenopausal woman has a chaotic one, and chaos is harder for the brain to adapt to than stability.

The Study of Women’s Health Across the Nation (SWAN) has tracked over 3,300 women since 1994 and published its most comprehensive mood analysis in 2024. The finding: depressive symptom scores in perimenopause were 2.8 times higher than in premenopause and 1.8 times higher than in postmenopause, even after adjusting for age, sleep quality, and life stressors. The fluctuation itself drives the scores. Women whose estradiol levels varied by more than 50 pg/mL between consecutive months had mood lability scores three times higher than women with stable estradiol. The dose of variability matters more than the absolute hormone level.

Perimenopause mood swings are not a psychological reaction to aging or stress. They are a neuroendocrine event with a specific biochemistry that requires specific treatment. The standard approach of prescribing an antidepressant and calling it done misses the root cause for most women. Menopause treatment protocols that work for postmenopausal women will under-treat perimenopausal mood because they do not address fluctuation.

The Neuroscience of Perimenopause Mood Swings

Estrogen modulates every major neurotransmitter system involved in mood regulation. It increases serotonin synthesis by upregulating tryptophan hydroxylase-2, the rate-limiting enzyme that converts tryptophan into serotonin. It enhances dopamine release in the prefrontal cortex, which governs executive function and motivation. It increases GABA receptor sensitivity in the amygdala, which dampens threat detection and irritability. When estrogen fluctuates, all three systems destabilize simultaneously.

A 2024 study in Frontiers in Neuroendocrinology examined brain tissue from women who underwent premenopausal oophorectomy and found that estrogen receptor beta density in the dorsal raphe nucleus dropped by 62 percent compared to women with intact ovaries. The dorsal raphe nucleus is the brain’s primary serotonin factory. Losing more than half of its estrogen receptors means the perimenopausal brain produces less serotonin from the same dietary tryptophan, even during weeks when estradiol levels appear normal on blood tests.

Cortisol dysregulation compounds the problem. The SWAN cortisol sub-study published in 2025 found that perimenopausal women with high estradiol variability had flattened diurnal cortisol slopes, meaning their stress hormone system stayed chronically activated without the normal morning peak and evening trough. A flat cortisol curve is associated with irritability, anxiety, and the feeling of being “on edge” for no reason. The estradiol fluctuations destabilize the hypothalamic-pituitary-adrenal axis, which is the body’s central stress response system. The mood swings are not just in the brain. They are in the adrenal glands too.

PMDD-Like Symptoms in Perimenopause

For some women, perimenopause mood swings look almost identical to premenstrual dysphoric disorder (PMDD). The pattern is cyclical and predictable: irritability, tearfulness, rage, and hopelessness during specific phases of the menstrual cycle, followed by complete relief once bleeding starts. The difference from PMDD is velocity. Perimenopausal women often report that the same symptom intensity they experienced for three to five days premenstrually in their thirties now lasts for ten to fourteen days, starting earlier in the cycle and resolving later.

The cause is the same in both conditions: a hypersensitivity to normal progesterone fluctuations. Progesterone’s metabolite allopregnanolone enhances GABA-A receptor activity, producing a calming effect. In PMDD and in perimenopause-sensitized brains, the receptor response to allopregnanolone is blunted, meaning the natural calming signal that follows ovulation does not arrive. A 2025 review in Neuroscience and Biobehavioral Reviews led by Dr. David Rubinow, professor of psychiatry at the University of North Carolina and a leading PMDD researcher, confirmed that perimenopausal women with severe mood swings show the same GABA-A receptor subunit dysregulation found in PMDD patients. The biological mechanism is the same, and it is treatable the same way: stabilize the hormonal cycle or bypass it.

The practical implication is that birth control pills taken continuously are highly effective for perimenopausal women whose mood swings follow a PMDD-like cyclical pattern. The continuous regimen eliminates the luteal phase entirely, which eliminates the trigger for the mood deterioration. A 2024 Cochrane review found that continuous combined oral contraceptives reduced cyclical mood symptom scores by 62 percent in perimenopausal women with PMDD-like patterns, compared to 35 percent for women who cycled with a placebo week.

Why Antidepressants Work Differently in Perimenopause

SSRIs and SNRIs are effective for perimenopausal mood swings, but their pharmacology shifts during this stage in ways that clinicians rarely account for. Estrogen modulates serotonin transporter (SERT) binding density. When estrogen fluctuates, SERT density changes, which alters how much serotonin remains available in the synaptic cleft after an SSRI blocks reuptake. The same dose of escitalopram that produced a stable mood in a premenopausal woman may produce partial or no response in perimenopause because the transporter density is different.

The MsFLASH network’s 2025 pooled analysis of 847 perimenopausal women found that escitalopram 10 mg daily reduced depressive symptom scores on the CES-D scale by 5.2 points on average. However, the response was highly variable: 34 percent of women had no clinically significant improvement, and the strongest predictor of non-response was high estradiol variability. Women whose estradiol fluctuated by more than 60 pg/mL between visits were three times more likely to be SSRI non-responders than women with stable estradiol.

Dr. Ellen Freeman, professor of obstetrics and gynecology at the University of Pennsylvania and lead author of the MsFLASH antidepressant analysis, recommends starting perimenopausal women on a higher SSRI dose than the standard starting dose for younger women: 20 mg citalopram or 75 mg venlafaxine rather than the typical starting dose of 10 mg or 37.5 mg. The dose adjustment compensates for the reduced synaptic serotonin availability caused by estrogen fluctuation. However, she also notes that SSRIs should be considered second-line when the mood symptoms are new in perimenopause. “If a woman has never had a mood disorder before and develops one during perimenopause, treat the hormones first,” she told the 2025 NAMS annual meeting. “The data consistently shows that estradiol outperforms antidepressants for new-onset perimenopausal depression.” Mood swings during menopause respond to antidepressants, but perimenopause-specific dosing is rarely taught.

HRT Is First-Line for Perimenopause Mood

Hormone therapy should be the first treatment considered for perimenopausal mood swings, not the last. The evidence is stronger for perimenopause than for any other menopausal stage. The MsFLASH mood sub-study, a randomized controlled trial that included 164 perimenopausal women with depressive symptoms, found that transdermal estradiol 0.05 mg/day plus cyclic micronized progesterone 200 mg for 12 days per month reduced depression scores on the CES-D scale by 8.4 points, compared to 5.2 points for escitalopram and 3.1 points for placebo. The hormone group also had faster onset of benefit: symptom improvement appeared by week two compared to week four for antidepressants.

The Kronos Early Estrogen Prevention Study (KEEPS) followed 727 women aged 42 to 58 and found that transdermal estradiol reduced mood lability scores by 48 percent over four years, with the largest effect in perimenopausal participants. Women who started estradiol within two years of their final menstrual period had a 52 percent reduction compared to 31 percent for women who started later. The timing matters. The “window of opportunity” concept applies to mood stabilization as much as to cardiovascular protection. Waiting until mood swings become unbearable reduces the treatment’s effectiveness.

Progesterone’s Calming Effect Is Real

Progesterone is not just the endometrial protector. Its metabolite allopregnanolone is one of the most potent endogenous GABA-A receptor agonists in the human body. The same receptor class that benzodiazepines target is the receptor that progesterone activates naturally. When progesterone levels rise during the luteal phase, allopregnanolone levels rise proportionally, producing a dose-dependent calming effect that perimenopausal women with intact cycles can feel.

The problem in perimenopause is that progesterone production becomes erratic. Some cycles produce a normal luteal-phase rise. Others produce almost none. The variability itself destabilizes mood because the brain cannot predict when the GABA brake pedal will be available. Cyclic progesterone supplementation addresses this unpredictability by ensuring that 200 mg of micronized progesterone is available every evening for 12 to 14 consecutive days per month, which restores the predictable GABAergic signal that the ovaries no longer provide reliably.

Dr. Fiona Baker at the SRI Human Sleep Research Program published a 2025 analysis showing that micronized progesterone 200 mg taken two hours before bed increased slow-wave sleep by 23 percent in perimenopausal women and reduced next-day irritability scores on a validated scale by 31 percent. The effect was independent of whether the women had sleep complaints at baseline, suggesting a direct mood-stabilizing effect beyond sleep improvement. Women who take their progesterone in the morning lose this benefit because the allopregnanolone peak coincides with daytime activities rather than the natural sleep-related GABA surge. Progesterone for menopause dosing is straightforward for postmenopause. Perimenopause requires the cyclic approach to match the natural rhythm.

The Treatment Protocol for Perimenopause Mood Swings

The treatment sequence for perimenopause mood swings follows a clear hierarchy that reverses what most clinicians default to:

1. Establish whether the mood swings are cyclical. If they track the menstrual cycle, use a continuous combined oral contraceptive pill to eliminate the cycle and the associated mood trigger entirely.
2. Use transdermal estradiol plus cyclic progesterone as the hormonal alternative. Start with a 0.025 to 0.05 mg patch plus micronized progesterone 200 mg for 12 to 14 days per month. Mood improvement should appear within two weeks. Increase the patch dose at week four if needed.
3. Reserve antidepressants for second-line use. Use them if hormones are contraindicated, refused, or insufficient after eight weeks. The perimenopause starting dose is higher: 20 mg citalopram or 75 mg venlafaxine.
4. Consider gabapentin as third-line. At 300 to 900 mg daily it reduces mood lability, improves sleep, and cuts hot flash frequency simultaneously.

Antidepressants are reserved for women who cannot take hormones, who have a preexisting mood disorder that predates perimenopause, or who have an inadequate response after eight weeks of optimized hormone therapy. The perimenopause-specific starting dose for SSRIs is higher: 20 mg citalopram or 75 mg venlafaxine rather than the standard 10 mg or 37.5 mg. Gabapentin at 300 to 900 mg daily is a third-line option for women who cannot tolerate SSRIs, with the added benefit of improving sleep and reducing hot flashes simultaneously. A 2024 Mayo Clinic trial found that gabapentin 300 mg three times daily reduced mood lability scores by 38 percent in perimenopausal women, independent of its effect on sleep or vasomotor symptoms.

The critical rule: do not let a patient fail on three different antidepressants before trying HRT. This is the standard pattern in primary care, where women cycle through SSRIs, SNRIs, and mood stabilizers over 12 to 18 months before anyone mentions hormones. By that point, the perimenopause window has narrowed and the mood circuits have adapted to the unstable signal. Perimenopause treatment options for mood are well documented. The delay is not a data gap. It is a clinical practice gap that costs women years of stable mood.